Feline Ocular FIP and Anterior Uveitis: GS-441524 Treatment

Bottom line

Ocular disease is a common, treatable manifestation of feline infectious peritonitis (FIP) — roughly one-third of FIP cats show eye involvement, and the modal picture is a bilateral pyogranulomatous panuveitis rather than an isolated anterior uveitis. [1][5] Since the arrival of nucleoside-analog antivirals, ocular FIP has shifted from a near-uniformly fatal sign to a manifestation that resolves in about 80% of cats treated with injectable remdesivir followed by oral GS-441524, at a median of roughly six weeks. [1] Treat the systemic disease and the eye usually follows — standard systemic dosing generally suffices, so the eye is not a pharmacologic sanctuary the way the CNS often is. [2] The salvage-relevant surveillance point is intraocular pressure: secondary glaucoma, not persistent inflammation, drives the worst ocular outcomes. [1]

Condition facts

Definition. Ocular FIP is intraocular inflammation caused by feline coronavirus (FCoV) that has acquired FIP-associated biotype changes. It is a pyogranulomatous, immune-complex–driven uveitis affecting one or both segments. [3]

Signalment. Classic FIP skews young (often under two years) and toward multi-cat or shelter/cattery backgrounds, though any age can be affected. Ocular signs may be the presenting or isolated organ finding, so a young cat with unexplained bilateral uveitis warrants FIP on the differential list. [1][5]

Pathophysiology. FCoV replicating in monocytes and macrophages breaks down the blood–ocular barrier, seeding pyogranulomatous inflammation into both segments. Anteriorly this yields fibrinous exudation into the anterior chamber, keratic precipitates, and aqueous flare; posteriorly it drives pyogranulomatous chorioretinitis and retinal vasculitis manifesting as perivascular cuffing, exudative retinal detachment, and optic neuritis. [3] This dual-segment, immune-complex mechanism explains why panuveitis dominates: in a 2025 case series, panuveitis accounted for 55% of ocular cases versus posterior (25%) and anterior (20%) uveitis alone, with bilateral involvement in 70%. [1]

Diagnosis: recognizing and confirming ocular FIP

On exam, the pattern is the diagnosis-prompting clue. Look for anterior-chamber fibrin, keratic precipitates ("mutton-fat" deposits on the corneal endothelium), aqueous flare, and iris changes anteriorly; and chorioretinitis, perivascular retinal cuffing, exudative retinal detachment, and optic neuritis posteriorly. [3] Bilateral, dual-segment disease in a young cat is what separates FIP from an isolated anterior uveitis and should trigger a systematic infectious-uveitis workup alongside FeLV, FIV, and toxoplasmosis. [3][5] Because ocular changes can develop progressively, repeated ophthalmoscopic examination is recommended in difficult-to-diagnose cases; FIP is a common cause of feline uveitis (diagnosed in roughly 16% of uveitis cases in two studies), so a normal early fundus exam does not exclude it. [5]

Confirmation rests on the whole clinical–clinicopathologic picture rather than any single ocular finding. Where effusion is present, fluid analysis is the highest-yield diagnostic step — Rivalta's test, cell count, cytology, and an albumin-to-globulin ratio, supplemented by FCoV testing. [5] Immunostaining (immunocytochemistry or immunohistochemistry) of affected tissue or effusion demonstrating FCoV antigen within macrophages remains the gold standard, though effusion immunostaining sensitivity is variable (reported 57–100%). [5] RT-qPCR detects FCoV RNA in blood, fluid, and tissue but is not specific for FIP on its own, since non-FIP cats can be viremic; a high viral load alongside compatible clinical findings raises suspicion. [5] In non-effusive cases — the common scenario when the eye is the presenting sign — a definitive antemortem diagnosis often requires invasive tissue sampling, so treatment decisions are frequently made on a strong clinical-plus-clinicopathologic composite. [5]

Treatment and efficacy: what the antiviral era delivers

Antiviral therapy is the determinant of ocular outcome. In the 2025 observational case series of 61 FIP cats, 20 (33%) had ocular disease; 85% received injectable remdesivir first (70% at 15–20 mg/kg) transitioning to oral GS-441524 (82% at 15–22 mg/kg), over an approximately 84-day course. Among the 11 cats with ophthalmic follow-up, clinical uveitis resolved in 9 (82%) at a median of 44 days (range 20–71), and overall survival was 80% (16/20). [1] Pooled evidence supports the same conclusion: a 2025 systematic review of 11 studies and 650 GS-441524–treated cats found an 84.6% overall success rate, and — critically for the eye — ocular-only cases responded at roughly 90%, nearly matching uncomplicated FIP and well above the ~68% seen in neurological disease. [2]

The practical takeaway is that the eye is not a pharmacologic sanctuary. FCoV disrupts the blood–ocular barrier that would otherwise limit drug diffusion, and standard systemic dosing that clears wet or uncomplicated FIP generally clears ocular disease too, without routine neuro-tier escalation. [2] The core evidence base is recent (2025) and no randomized controlled trial of ocular FIP therapy has yet been published, so protocols remain observational.

Dosing and ocular drug penetration

GS-441524 is the active nucleoside analog; remdesivir is its injectable prodrug, hydrolyzed in vivo to GS-441524. Best-outcome dosing in the systematic review clustered at 5–10 mg/kg once daily (or the equivalent subcutaneous dose) for at least 12 weeks, adjusted upward for severity, and split to twice daily where absorption or trough concentrations demand it. [2] Ocular cases in the case series often ran higher (15–22 mg/kg oral GS-441524), reflecting clinician caution with sanctuary-adjacent disease, though the efficacy data suggest standard dosing is usually adequate. [1][2]

Pharmacokinetics support once-daily dosing: after a single 15 mg/kg IV remdesivir dose in cats, mean peak GS-441524 plasma concentration was ~2632 ng/mL at 1 hour with an elimination half-life of ~5 hours, sustaining exposure across the interval. [4] Therapeutic drug monitoring, however, is not yet a reliable optimization tool — trough concentrations did not correlate cleanly with remission (15% of cats in remission had troughs below 100 ng/mL), so dose to clinical and clinicopathologic response, not to a target trough. [4] Availability and legality vary by jurisdiction: legally compounded, veterinarian-prescribed oral GS-441524 and injectable remdesivir are available in the UK, Australia, the Netherlands, and increasingly the US and Canada, but you must reconcile product and regulatory status locally. [2]

Adjunct anti-inflammatory care and monitoring

Antivirals treat the cause; topical therapy controls the intraocular inflammation while the virus clears. Standard adjunctive care for the anterior segment is topical 1% prednisolone acetate or 0.1% dexamethasone, dosed frequently (every 4–6 hours) during active uveitis and tapered as flare and fibrin resolve. Topical 1% atropine ointment provides cycloplegia for comfort and helps prevent posterior synechiae, with the ointment vehicle preferred in cats to reduce drooling. [6] The critical caveat: atropine and other cycloplegics are contraindicated once intraocular pressure is elevated, because they can worsen secondary glaucoma. [6] Systemic corticosteroids are generally avoided or minimized while relying on antiviral clearance, given concern about immunosuppression during active infection. [3][6]

Monitoring centers on intraocular pressure, not inflammation alone. Secondary glaucoma developed in 20% of ocular FIP cats and accounted for every enucleation (10%, unilateral) in the case series — the eye, not viral status, governed the worst ocular outcomes. [1] Resolution of aqueous flare does not guarantee a pressure-safe eye, so tonometry belongs in every recheck. Where IOP rises, add topical antiglaucoma therapy, stop cycloplegics, and escalate ophthalmic follow-up. [1][6]

Prognosis

The prognosis for ocular FIP in the antiviral era is genuinely good and worth conveying to owners. Expect roughly 80% overall survival and about 82% clinical uveitis resolution on remdesivir/GS-441524, with resolution at a median near 44 days and a total treatment course of at least 12 weeks. [1][2] The sight-limiting risk is secondary glaucoma rather than treatment failure, and enucleation — when needed — is typically unilateral for an uncontrolled-pressure eye, not a systemic-outcome event. [1] This is an evidence summary, not a treatment protocol: drug selection, dosing, monitoring, and prognosis must be individualized to the patient and reconciled with current product availability and regulatory status in your jurisdiction.

Frequently Asked Questions

How common are ocular signs in cats with FIP?

Ocular disease is common. In a 2025 observational case series of 61 FIP cats, 33% (20/61) had ocular involvement, and overall FIP guidelines cite ocular involvement in roughly 16% of cases. Panuveitis was the most common phenotype (55% of ocular cases), followed by posterior (25%) and anterior (20%) uveitis, with bilateral disease in 70%. [1][5]

Does GS-441524/remdesivir resolve FIP-associated uveitis?

Largely, yes. In the 2025 case series, cats treated with injectable remdesivir followed by oral GS-441524 achieved clinical uveitis resolution in about 82% (9 of 11 with follow-up) at a median of 44 days, with 80% overall survival. A 2025 systematic review found ocular-only FIP responded at roughly 90%, nearly matching uncomplicated cases. [1][2]

Does ocular FIP require higher GS-441524 doses like neurological FIP?

Current evidence does not support routine neuro-tier escalation for the eye alone. Ocular-only cases responded to standard dosing (best outcomes at 5-10 mg/kg once daily for at least 12 weeks) at roughly 90%, well above the ~68% seen in neurological disease. FCoV disrupts the blood-ocular barrier, so standard systemic exposure generally reaches the eye; dosing must still be individualized. [2]

What is the main sight-threatening complication of ocular FIP?

Secondary glaucoma. In the 2025 case series it developed in 20% of ocular FIP cats and accounted for every enucleation (10%, unilateral, for uncontrolled pressure). Intraocular pressure monitoring during antiviral therapy is the salvage-relevant surveillance point — resolution of inflammation does not guarantee a pressure-safe eye. [1]

What adjunctive topical therapy should I use for FIP uveitis?

Topical 1% prednisolone acetate or 0.1% dexamethasone every 4-6 hours during active uveitis, tapered as flare and fibrin resolve, plus 1% atropine ointment for cycloplegia and comfort. Atropine and other cycloplegics are contraindicated once intraocular pressure is elevated, because they can worsen secondary glaucoma. [6]

How is ocular FIP confirmed diagnostically?

Confirmation rests on the whole clinical-clinicopathologic picture. Effusion analysis (Rivalta's test, cytology, albumin-to-globulin ratio) is highest-yield when fluid is present, and FCoV antigen immunostaining of tissue or effusion is the gold standard. RT-qPCR detects FCoV RNA but is not specific for FIP on its own. In non-effusive ocular presentations, antemortem diagnosis often relies on a strong clinical composite. [5]

Does therapeutic drug monitoring help optimize GS-441524 dosing?

Not reliably. After a single 15 mg/kg IV remdesivir dose, mean peak GS-441524 was ~2632 ng/mL with a ~5-hour half-life, supporting once-daily dosing. But trough concentrations did not correlate cleanly with remission — 15% of cats in remission had troughs below 100 ng/mL — so dose to clinical and clinicopathologic response rather than to a target trough. [4]

What survival and resolution timelines should I counsel owners on?

Expect roughly 80% overall survival and about 82% clinical uveitis resolution on remdesivir/GS-441524, with resolution at a median near 44 days and a total course of at least 12 weeks. The main sight-limiting risk is secondary glaucoma rather than treatment failure. [1][2]